1 ; EFFECTS PATIENTS CF PROPERTIES MUCUS FROM WHAT ARE ON PHYSICAL THE CALCIUM OF
2 ; EFFECTS SUBMUCOSAL CF MUCUS AND INFECTION TRACT GLANDS HYPERSECRETION ON IN RESPIRATORY CAN ONE BETWEEN DISTINGUISH THE OF
3 ; PATIENTS GLYCOPROTEINS CF SUBJECTS FROM ARE SALIVARY NORMAL THOSE DIFFERENT HOW OF
4 ; IS COMPOSITION LIPID CF WHAT SECRETIONS RESPIRATORY THE OF
5 ; ABNORMAL IS CF MUCUS
6 ; BRONCHIAL IS THERAPEUTIC SPUTUM CF PATIENTS PROPERTIES FROM WATER WHAT OTHER SECRETIONS OR ON ELASTICITY EFFECT PHYSICAL THE AGENTS VISCOSITY OF
7 ; PATIENTS GLYCOPROTEINS CF SUBJECTS DEGRADED FROM MUCUS ARE COMPARED AS IN TO NORMAL THOSE DIFFERENTLY
8 ; CF DIFFERENCES AND WHAT HAVE RESPIRATORY DESCRIBED HISTOCHEMICAL NORMAL EPITHELIA BETWEEN BEEN
9 ; IS ASSOCIATION LIVER CF CIRRHOSIS AND WHAT VITAMIN DISEASE IN BETWEEN THE METABOLISM
10 ; PATIENTS IS WITH CF WHAT VITAMIN ROLE IN THE THERAPY OF
11 ; IS MECONIUM AND WHAT DIFFERENCE PLUG BETWEEN THE SYNDROME ILEUS
12 ; PATIENTS CF SMALL ABNORMALITIES WHAT AMINO HAVE IN DESCRIBED TRANSPORT BOWEL THE ACID BEEN OF
13 ; PATIENTS CF PANCREATITIS WHAT BIOCHEMICAL OR ARE CLINICAL FEATURES IN THE OF
14 ; FOR PATIENTS WITH CF WHAT TESTS BE PANCREATIC FUNCTION IN EVALUATION NON-INVASIVE CAN EXOCRINE THE PERFORMED OF
15 ; CF WHAT OR ARE MANIFESTATIONS HEPATIC THE COMPLICATIONS OF
16 ; ILEUS LIVER CF PERIOD MECONIUM AND WHAT ARE DISEASE AFTER EXCLUDE NEONATAL THE COMPLICATIONS GASTROINTESTINAL OF
17 ; FOR IS ENZYME REGIMEN MOST CF PATIENTS WHAT EFFECTIVE USE PANCREATIC IN TREATMENT THE SUPPLEMENTS OF
18 ; BILE IS OF THERAPEUTIC SUPPLEMENTATION BENEFIT CF PATIENTS SALTS TO DIETARY WITH
19 ; PATIENTS ENZYME CF WHAT PANCREATIC HAVE REPORTED IN COMPLICATIONS THERAPY BEEN OF
20 ; PATIENTS IS CF WITH WHAT FATTY EFFECT ESSENTIAL TREATMENT THE ACID SUPPLEMENTS OF
21 ; PATIENTS CF AFFECT ABSORB DOES INSUFFICIENCY PANCREATIC ABILITY OR IN TO THEIR METABOLIZE IRON
22 ; IS CF WHAT FREQUENCY POPULATIONS IN THE NON-CAUCASIAN OF
23 ; DISEASES ASSOCIATION CF FOUND WHAT CONGENITAL HAVE OR IN CONDITIONS HEREDITARY BEEN WITH
24 ; PATIENTS IS CF CHARACTERISTICS WHAT ARE IN WHOM MANIFESTED THE INCOMPLETELY OF
25 ; FOR IS CF INVOLVES THAN THERE WHAT BASIS MORE GENETIC GENE THAT EVIDENCE THE ONE
26 ; IS CF WHAT HETEROZYGOTE IN THE ADVANTAGE
27 ; BOTH IS CF PAIRS WHAT BIOCHEMICAL OR HAVE CLINICAL MANIFESTATIONS IN CONCORDANCE WHOM SIBLING THE OF
28 ; FERTILITY IS CF WHAT MALE INCIDENCE IN THE OF
29 ; SYSTEM IS CF WHAT MALE OR IN FEMALE THE PATHOLOGY REPRODUCTIVE OF
30 ; WITH CF COUNSELING RESULTS WHAT ARE FAMILIES GENETIC CHILDREN THE OF
31 ; EFFECTS OF SOCIAL CF PATIENTS AND WHAT OR ARE ON FAMILIES THEIR PSYCHOLOGICAL THE MAJOR
32 ; PATIENTS FACTORS CF WHAT INFLUENCE IN PRESCRIBED COMPLIANCE THERAPY WITH
33 ; FACTORS WHAT TESTS OR ERRONEOUS TO CONDITIONS SWEAT LEAD
34 ; AND TECHNIQUES CLASSICAL ANALYSIS SWEAT QUANTITATIVE WHAT ALTERNATIVE ADVANTAGES FOR CHLORIDE IONTOPHORESIS RELATIVE THAN OTHER TESTING AVAILABLE PILOCARPINE GIBSON-COOKE THEIR THE DISADVANTAGES OF WITH ARE TITRIMETRIC TEST
35 ; CF FOUND TESTS ANY HAVE PATIENT TO NORMAL CONSISTENTLY SWEAT HAS BEEN
36 ; PATIENTS IS CF POTASSIUM FROM WHAT CONCENTRATION IN SWEAT THE OF
37 ; FOR CF FACTORS INFANTS AND WHAT RESULTS TESTS AVAILABLE ARE ERRONEOUS NEWBORN TO TECHNIQUES CONTRIBUTE THESE SCREENING OF
38 ; DIAGNOSED CF BE PRENATALLY CAN
39 ; HETEROZYGOTES FOR CF MAY BE IDENTIFIED HOW
40 ; USEFUL FOR PERIOD CF MAY THAN DIAGNOSIS WHAT OTHER BE TECHNIQUES BEYOND NEONATAL SWEAT THE TEST OF
41 ; PATIENTS IS CF VITAMIN IN NORMAL METABOLISM
42 ; SECRETION PATIENTS CF ABNORMALITIES WHAT OR IN INSULIN METABOLISM OCCUR OF
43 ; IS CHLORIDE CF SODIUM SALT TRANSPORT/PERMEABILITY ABNORMAL IN AND/OR
44 ; PATIENTS CF DIFFERENCES FROM ENZYMATIC THERE WHAT AND ARE OR NON-CF STRUCTURAL BETWEEN FIBROBLASTS
45 ; OF PATIENTS CF ABNORMALITIES WHAT HAVE IN DESCRIBED METABOLISM BEEN PROSTAGLANDIN
46 ; PATIENTS CF GALACTOSYLTRANSFERASE PROPERTIES FROM AND WHAT ARE THE ENZYMES ACTIVITY OF
47 ; PATIENTS CF DIFFERENCES SUBJECTS AND WHAT FUNCTION HAVE OR HORMONES IN NORMAL DESCRIBED BETWEEN THE BEEN METABOLISM OF
48 ; PATIENTS CF DO FROM GROW RATE NORMAL AT FIBROBLASTS
49 ; PATIENTS IS CF METHYLATION POLYAMINE OR IN RNA NORMAL METABOLISM
50 ; DEFECTS OF CYCLIC CF PATIENTS WHAT HAVE OR IN DESCRIBED NUCLEOTIDES THE METABOLISM BEEN SYNTHESIS
51 ; PATIENTS FIBROSIS UNIDENTIFIED SOME PLAY ACTIVE DESCRIBED CF CIRCULATING WHAT HAVE ROLE TO MOLECULES PATHOGENETIC '' OR IN `` CYSTIC BIOLOGICALLY FACTORS THOUGHT ARE SECRETED BEEN
52 ; PATIENTS IS CF ABOUT PROLACTIN WHAT KNOWN IN
53 ; SECRETORY PATIENTS CF PROTECT BACTERIAL DOES INFECTION AGAINST OR IGA COLONIZATION
54 ; PATIENTS IS CF WHAT OR DISEASE IN TO HYPERSENSITIVITY ALLERGY THE RELATIONSHIP LUNG OF
55 ; PATIENTS CF BACTERIAL ENDOGENOUS WHAT AND ORIGIN ARE OR IN PROTEASES BETWEEN THE INTERACTIONS ANTIPROTEASES LUNGS OF
56 ; PATIENTS IS CF BACTERIAL AND WHAT NUTRITION INFECTION HOST AGAINST PULMONARY IN BETWEEN THE RELATIONSHIP DEFENSES
57 ; PATIENTS IS CF ANTIBODIES CIRCULATING WHAT PSEUDOMONAS ROLE IN TO AERUGINOSA THE PATHOPHYSIOLOGIC OF
58 ; IMMUNOLOGIC IS CF PATIENTS INFECTION WHAT RESPONSE PULMONARY IN TO THE
59 ; IMMUNOLOGIC PATIENTS CF FOUND ABNORMALITIES WHAT HAVE IN BEEN
60 ; EFFECTS CF CIRCULATION WHAT ARE ON PULMONARY THE OF
61 ; PATIENTS IS CF THERE MUCOCILIARY TRACT IN DEFECT CLEARANCE RESPIRATORY TRANSPORT THE OF
62 ; PATIENTS CF WHAT ARE DISEASE CLINICAL FEATURES IN THE LUNG OF
63 ; PATIENTS CF CHARACTERISTICS WHAT INFLAMMATION BIOCHEMICAL OR ARE IN AIRWAY THE MICROSCOPIC OF
64 ; PATIENTS DAY CF GREATER THAN DOES FUNCTION IN PERIODS HOW TIME LUNG CHANGE WITH
65 ; PATIENTS CF ABNORMALITIES WHAT FUNCTION ARE PULMONARY IN THE OF
66 ; PATIENTS CF WHAT ARE DISEASE FEATURES IN PATHOLOGIC THE LUNG OF
67 ; FOR IS PATIENTS AN WHAT EPISODE HAVE HAD FAILURE RESPIRATORY WHO PROGNOSIS THE OF
68 ; EFFECTS PATIENTS CF WHAT BRONCHODILATORS ARE IN THE OF
69 ; PATIENTS IS CF WHAT PNEUMOTHORAX TREAT IN TO WAY THE BEST
70 ; FOR IS CF PATIENTS AND WHAT IN HEMOPTYSIS PROGNOSIS TREATMENT THE OF
71 ; FOR IS WHEEZING FIBROSIS INFANTS AND WHAT CYSTIC PROGNOSIS THE WITH
72 ; FOR IS CF PATIENTS POLYPS WHAT IN NASAL TREATMENT THE BEST
73 ; PATIENTS IS CF EFFECTIVE IN HOW LAVAGE BRONCHIAL
74 ; PATIENTS WITH CF RESULTS WHAT VENTILATION ARE IN RESPIRATORY FAILURE MECHANICAL THE OF
75 ; FOR IS CF PATIENTS WHAT COR PULMONARY IN PULMONALE HYPERTENSION AND/OR TREATMENT THE BEST
76 ; EFFECTS PATIENTS CF WHAT FUNCTION ARE ON IN TRAINING PROGRAMS THE EXERCISE LUNG OF
77 ; PATIENTS CF PROMOTING MUCUS FROM WHAT EFFECTIVE ARE IN CLEARANCE TECHNIQUES THE LUNGS OF
78 ; PATIENTS SPECIAL THERE DIFFERENT CF WHAT TO CONSIDERATIONS FOR IE OTHER PROBLEMS OR IN TREATMENT THE WITH OF PHARMACODYNAMICS ARE PECULIAR ANTIBIOTICS
79 ; ANTIBIOTICS IS CF PATIENTS WHAT ROLE IN ORALLY ADMINISTERED THE TREATMENT OF
80 ; IS PENICILLINS COMBINATION THAN AND WHAT MORE EFFECTIVE AMINOGLYCOSIDES EITHER ALONE THAT EVIDENCE THE THERAPY SEMISYNTHETIC WITH
81 ; PATIENTS CF EFFECTIVE MUCOLYTIC ARE IN TREATMENT HOW INHALATIONS AGENTS THE OF
82 ; PATIENTS IS CF WHAT AEROSOLS ROLE DISEASE IN TREATMENT THE LUNG OF
83 ; ALVEOLAR IS LEUKOCYTES CF PATIENTS BACTERIAL BY WHAT ROLE OR DISEASE MACROPHAGES IN PHAGOCYTOSIS THE LUNG POLYMORPHONUCLEAR OF
84 ; INFLUENZAE IS CF PATIENTS AND WHAT PSEUDOMONAS IN AERUGINOSA HAEMOPHILUS BETWEEN THE RELATIONSHIP
85 ; PATIENTS CF DO EVER INFECTION THAN OTHER WHAT DEVELOP SO IN IF ORGANS THE LUNG
86 ; INFLUENZAE IS CF PATIENTS THAN WHAT OTHER BACTERIA PSEUDOMONAS STAPHYLOCOCCUS ROLE OR PATHOGENESIS IN AERUGINOSA AUREUS DISEASE HAEMOPHILUS THE LUNG OF
87 ; PATIENTS IS CF WHAT FUNGI ROLE PATHOGENESIS DISEASE IN THE LUNG OF
88 ; PATIENTS IS CF INFECTION WHAT VIRAL ROLE DISEASE IN THE LUNG OF
89 ; PATIENTS IS CF EPIDEMIOLOGY DO WHAT OTHER PSEUDOMONAS OR SPECIFICALLY SPREAD IN AERUGINOSA TO INDIVIDUALS FAMILY THE OF
90 ; FOR PATIENTS FACTORS CF WHAT PSEUDOMONAS ARE APPEARANCE RESPONSIBLE AERUGINOSA IN MUCOID STRAINS THE OF
91 ; CF THAN WHAT OTHER PANCREATIC INSUFFICIENCY ARE DISEASE MANIFESTATIONS OR UNUSUAL EXOCRINE THE LUNG OF
92 ; FOR IS PATIENTS WITH CF WHAT SURVIVAL PROGNOSIS THE OF
94 ; MODELS CF WHAT ANIMAL AVAILABLE ARE RELEVANT TO WHICH
95 ; PATIENTS CF MUSCLE FOUND ABNORMALITIES WHAT FUNCTION HAVE OR SKELETAL IN STRUCTURE BEEN OF
96 ; PATIENTS IS AN EG CF THERE PROBLEMS PERIODONTAL DENTAL INCIDENCE OR DISEASE IN CARIES INCREASED OF
97 ; PATIENTS IS CF BY BLOOD CELLS ABNORMAL RED IN OXYGEN TRANSPORT
98 ; EFFECTS DEVELOPMENT CF SYSTEM BRAIN AND WHAT CENTRAL FUNCTION ARE ON NERVOUS AND/OR THE OF
99 ; PATIENTS CF THERE ABNORMALITIES ARE TASTE IN OF
100 ; FOR IS CF PATIENTS HYPERTROPHIC AND WHAT OSTEOARTHROPATHY INCIDENCE IN TREATMENT THE OF